AtriCure (ATRC) Stock Forecast, Price Target & Predictions
ATRC Stock Forecast
AtriCure stock forecast is as follows: an average price target of $49.57 (represents a 75.72% upside from ATRC’s last price of $28.21) and a rating consensus of 'Buy', based on 5 wall street analysts offering a 1-year stock forecast.
ATRC Price Target
The average price target for AtriCure (ATRC) is $49.57 based on 1-year price targets from 5 Wall Street analysts in the past 3 months, with a price target range of $81.00 to $26.00. This represents a potential 75.72% upside from ATRC's last price of $28.21.
ATRC Analyst Ratings
According to 5 Wall Street analysts, AtriCure's rating consensus is 'Buy'. The analyst rating breakdown for ATRC stock is 0 'Strong Buy' (0.00%), 5 'Buy' (100.00%), 0 'Hold' (0.00%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).
AtriCure Price Target by Analyst
| Date | Analyst | Company | Price Target | Price when Published | Price Target/Price when Published | Price Target/Last Closing Price |
|---|---|---|---|---|---|---|
| Jul 31, 2024 | Rick Wise | Stifel Nicolaus | $26.00 | $22.00 | 18.18% | -7.83% |
| Jul 31, 2024 | Matt O'Brien | Piper Sandler | $40.00 | $22.00 | 81.82% | 41.79% |
| Jul 31, 2024 | Marie Thibault | BTIG | $53.00 | $22.00 | 140.91% | 87.88% |
| May 02, 2024 | Mike Matson | Needham | $40.00 | $24.76 | 61.55% | 41.79% |
| May 02, 2024 | Marie Thibault | BTIG | $58.00 | $24.76 | 134.25% | 105.60% |
| Apr 23, 2024 | Suraj Kalia | Oppenheimer | $32.00 | $22.71 | 40.91% | 13.43% |
| Feb 06, 2023 | - | Canaccord Genuity | $81.00 | $47.20 | 71.61% | 187.13% |
| Dec 19, 2022 | Mike Matson | Needham | $58.00 | $41.37 | 40.20% | 105.60% |
| Aug 03, 2022 | Matt O'Brien | Piper Sandler | $55.00 | $49.69 | 10.69% | 94.97% |
| May 04, 2022 | - | Needham | $67.00 | $54.63 | 22.64% | 137.50% |
The latest AtriCure stock forecast, released on Jul 31, 2024 by Rick Wise from Stifel Nicolaus, set a price target of $26.00, which represents a 18.18% increase from the stock price at the time of the forecast ($22.00), and a -7.83% decrease from ATRC last price ($28.21).
AtriCure Price Target by Period
| 1M | 3M | 12M | |
|---|---|---|---|
| # Anlaysts | - | 3 | 6 |
| Avg Price Target | - | $39.67 | $41.50 |
| Last Closing Price | $28.21 | $28.21 | $28.21 |
| Upside/Downside | -100.00% | 40.62% | 47.11% |
In the current month, the average price target of AtriCure stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to AtriCure's last price of $28.21. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.
Analyst Ratings Upgrades/Downgrades
| Date | Company | Previous Rating | New Rating | Rating Change |
|---|---|---|---|---|
| Jul 31, 2024 | Needham | Underperform | Underperform | Hold |
| Jul 31, 2024 | Piper Sandler | Buy | Buy | Hold |
| Jul 31, 2024 | Piper Sandler | Overweight | Overweight | Hold |
| Jul 31, 2024 | BTIG | Buy | Buy | Hold |
| Jul 08, 2024 | Oppenheimer | Buy | Buy | Hold |
| Jul 08, 2024 | Needham | Underperform | Underperform | Hold |
| May 02, 2024 | Oppenheimer | Underperform | Underperform | Hold |
| May 02, 2024 | UBS | Buy | Buy | Hold |
| May 02, 2024 | Needham | Buy | Buy | Hold |
| May 02, 2024 | BTIG | Buy | Buy | Hold |
AtriCure's last stock rating was published by Needham on Jul 31, 2024. The company gave ATRC a "Underperform" rating, the same as its previous rate.
AtriCure Financial Forecast
AtriCure Revenue Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | $98.29M | $100.92M | $93.49M | $88.03M | $83.25M | - | $74.58M | $73.22M | $70.46M | $71.38M | $59.27M | $57.73M | $54.76M | $40.82M | $53.23M | $61.32M | $56.61M |
| Avg Forecast | $154.30M | $141.79M | $147.11M | $137.46M | $137.58M | $127.38M | $132.11M | $123.23M | $120.66M | $112.26M | $116.24M | $106.86M | $103.68M | $96.65M | $97.55M | $88.48M | $87.78M | $81.79M | $79.60M | $71.17M | $72.66M | $68.59M | $61.09M | $56.06M | $58.02M | $49.37M | $35.94M | $55.50M | $60.07M | $55.12M |
| High Forecast | $155.33M | $142.74M | $148.09M | $138.38M | $138.50M | $128.23M | $133.00M | $124.05M | $121.46M | $112.71M | $117.02M | $107.57M | $104.37M | $99.02M | $98.20M | $89.07M | $88.37M | $82.33M | $79.60M | $71.92M | $73.42M | $69.31M | $61.73M | $56.65M | $58.63M | $49.89M | $36.32M | $56.08M | $60.70M | $55.70M |
| Low Forecast | $153.27M | $140.84M | $146.13M | $136.54M | $136.66M | $126.53M | $131.23M | $122.40M | $119.85M | $111.97M | $115.46M | $106.14M | $102.98M | $95.42M | $96.90M | $87.89M | $87.19M | $81.24M | $79.60M | $70.38M | $71.86M | $67.84M | $60.41M | $55.45M | $57.38M | $48.83M | $35.55M | $54.89M | $59.41M | $54.51M |
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | - | 1 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.02% | 1.03% | 1.06% | 1.00% | 1.02% | - | 1.05% | 1.01% | 1.03% | 1.17% | 1.06% | 0.99% | 1.11% | 1.14% | 0.96% | 1.02% | 1.03% |
AtriCure's average Quarter revenue forecast for Dec 23 based on 1 analysts is $103.68M, with a low forecast of $102.98M, and a high forecast of $104.37M. ATRC's average Quarter revenue forecast represents a 5.48% increase compared to the company's last Quarter revenue of $98.29M (Sep 23).
AtriCure EBITDA Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | - | 1 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | $-8.09M | $-4.14M | $-5.78M | $-4.14M | $-10.72M | - | $-11.26M | $-9.77M | $101.42M | $-12.33M | $-13.57M | $-15.10M | $-1.24M | $-4.54M | $-12.73M | $-12.41M | $-5.78M |
| Avg Forecast | $-31.88M | $-29.30M | $-30.40M | $-28.40M | $-28.43M | $-26.32M | $-27.30M | $-25.46M | $-24.93M | $-23.19M | $-24.02M | $-13.20M | $-21.42M | $-19.97M | $-20.16M | $-12.00M | $-18.14M | $-16.90M | $-16.45M | $-10.91M | $-8.27M | $-14.17M | $-12.33M | $-13.21M | $-15.10M | $-1.87M | $-6.73M | $-12.42M | $-12.11M | $-6.21M |
| High Forecast | $-31.67M | $-29.10M | $-30.19M | $-28.21M | $-28.24M | $-26.14M | $-27.11M | $-25.29M | $-24.76M | $-23.13M | $-23.86M | $-10.56M | $-21.28M | $-19.71M | $-20.02M | $-9.60M | $-18.02M | $-16.79M | $-16.45M | $-8.73M | $-6.61M | $-14.02M | $-9.86M | $-10.57M | $-12.08M | $-1.50M | $-5.38M | $-9.93M | $-9.68M | $-4.97M |
| Low Forecast | $-32.09M | $-29.49M | $-30.60M | $-28.59M | $-28.62M | $-26.49M | $-27.48M | $-25.63M | $-25.10M | $-23.29M | $-24.18M | $-15.84M | $-21.56M | $-20.46M | $-20.29M | $-14.40M | $-18.26M | $-17.01M | $-16.45M | $-13.09M | $-9.92M | $-14.32M | $-14.80M | $-15.85M | $-18.12M | $-2.25M | $-8.08M | $-14.90M | $-14.53M | $-7.45M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.41% | 0.21% | 0.48% | 0.23% | 0.63% | - | 1.03% | 1.18% | -7.16% | 1.00% | 1.03% | 1.00% | 0.66% | 0.67% | 1.03% | 1.03% | 0.93% |
6 analysts predict ATRC's average Quarter EBITDA for Dec 21 to be $-8.27M, with a high of $-6.61M and a low of $-9.92M. This is -108.15% lower than AtriCure's previous annual EBITDA (Sep 21) of $101.42M.
AtriCure Net Income Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | - | 1 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| Net Income | - | - | - | - | - | - | - | - | - | - | - | - | - | $-9.05M | $-5.12M | $-6.48M | $-4.17M | $-12.27M | - | $-15.18M | $-13.74M | $97.11M | $-16.25M | $-16.92M | $-18.56M | $-4.95M | $-8.24M | $-16.41M | $-16.10M | $-9.36M |
| Avg Forecast | $-2.38M | $-4.85M | $-5.26M | $-8.98M | $-4.93M | $-6.96M | $-7.29M | $-9.91M | $-6.99M | $-9.14M | $-7.88M | $-17.80M | $-10.54M | $-14.28M | $-13.90M | $-16.18M | $-8.26M | $125.89M | $-13.69M | $-14.71M | $-11.63M | $114.45M | $-16.25M | $-16.46M | $-18.56M | $-7.47M | $-12.22M | $-16.01M | $-15.70M | $-10.06M |
| High Forecast | $-2.36M | $-4.81M | $-5.22M | $-8.90M | $-4.89M | $-6.90M | $-7.23M | $-9.82M | $-6.93M | $-8.69M | $-7.81M | $-14.24M | $-9.59M | $-11.98M | $-13.78M | $-12.94M | $-8.19M | $151.07M | $-13.69M | $-11.77M | $-9.30M | $137.34M | $-13.00M | $-13.17M | $-14.85M | $-5.97M | $-9.78M | $-12.81M | $-12.56M | $-8.04M |
| Low Forecast | $-2.40M | $-4.90M | $-5.31M | $-9.05M | $-4.98M | $-7.02M | $-7.35M | $-10.00M | $-7.05M | $-10.06M | $-7.95M | $-21.36M | $-11.02M | $-15.67M | $-14.02M | $-19.42M | $-8.33M | $100.71M | $-13.69M | $-17.65M | $-13.95M | $91.56M | $-19.50M | $-19.75M | $-22.27M | $-8.96M | $-14.67M | $-19.21M | $-18.84M | $-12.07M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.63% | 0.37% | 0.40% | 0.50% | -0.10% | - | 1.03% | 1.18% | 0.85% | 1.00% | 1.03% | 1.00% | 0.66% | 0.67% | 1.03% | 1.03% | 0.93% |
AtriCure's average Quarter net income forecast for Dec 21 is $-11.63M, with a range of $-13.95M to $-9.30M. ATRC's average Quarter net income forecast represents a -111.97% decrease compared to the company's last Quarter net income of $97.11M (Sep 21).
AtriCure SG&A Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | - | 1 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| SG&A | - | - | - | - | - | - | - | - | - | - | - | - | - | $61.60M | $63.78M | $60.06M | $55.50M | $57.27M | - | $56.12M | $53.71M | $49.87M | $56.96M | $49.21M | $49.07M | $33.75M | $24.90M | $42.75M | $47.00M | $40.28M |
| Avg Forecast | $108.48M | $99.68M | $103.42M | $96.64M | $96.72M | $89.55M | $92.88M | $86.63M | $84.82M | $78.92M | $81.72M | $65.78M | $72.89M | $67.95M | $68.58M | $59.80M | $61.71M | $64.66M | $55.96M | $54.36M | $45.45M | $58.78M | $56.96M | $47.88M | $49.07M | $34.71M | $25.27M | $41.71M | $45.86M | $43.26M |
| High Forecast | $109.20M | $100.35M | $104.11M | $97.28M | $97.37M | $90.15M | $93.50M | $87.21M | $85.39M | $79.24M | $82.27M | $78.93M | $73.37M | $69.61M | $69.04M | $71.76M | $62.12M | $77.59M | $55.96M | $65.23M | $54.54M | $70.53M | $68.35M | $57.45M | $58.88M | $35.07M | $25.54M | $50.05M | $55.03M | $51.92M |
| Low Forecast | $107.75M | $99.02M | $102.73M | $95.99M | $96.08M | $88.96M | $92.26M | $86.05M | $84.26M | $78.72M | $81.17M | $52.62M | $72.40M | $67.08M | $68.12M | $47.84M | $61.30M | $51.73M | $55.96M | $43.49M | $36.36M | $47.02M | $45.57M | $38.30M | $39.26M | $34.33M | $24.99M | $33.37M | $36.69M | $34.61M |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.91% | 0.93% | 1.00% | 0.90% | 0.89% | - | 1.03% | 1.18% | 0.85% | 1.00% | 1.03% | 1.00% | 0.97% | 0.99% | 1.03% | 1.03% | 0.93% |
AtriCure's average Quarter SG&A projection for Dec 23 is $72.89M, based on 1 Wall Street analysts, with a range of $72.40M to $73.37M. The forecast indicates a 18.32% rise compared to ATRC last annual SG&A of $61.60M (Sep 23).
AtriCure EPS Forecast
| Dec 26 | Sep 26 | Jun 26 | Mar 26 | Dec 25 | Sep 25 | Jun 25 | Mar 25 | Dec 24 | Sep 24 | Jun 24 | Mar 24 | Dec 23 | Sep 23 | Jun 23 | Mar 23 | Dec 22 | Sep 22 | Jul 22 | Mar 22 | Dec 21 | Sep 21 | Jun 21 | Mar 21 | Dec 20 | Sep 20 | Jun 20 | Mar 20 | Dec 19 | Sep 19 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| # Analysts | 3 | 3 | 3 | 3 | 4 | 4 | 4 | 4 | 3 | 6 | 3 | - | 1 | 8 | 5 | 4 | 4 | 3 | 5 | 3 | 6 | 4 | 6 | 8 | 5 | 5 | 10 | 7 | 4 | 4 |
| EPS | - | - | - | - | - | - | - | - | - | - | - | - | - | $-0.20 | $-0.11 | $-0.14 | $-0.09 | $-0.27 | - | $-0.33 | $-0.30 | $2.15 | $-0.36 | $-0.38 | $-0.42 | $-0.11 | $-0.20 | $-0.42 | $-0.42 | $-0.25 |
| Avg Forecast | $-0.05 | $-0.10 | $-0.11 | $-0.19 | $-0.11 | $-0.15 | $-0.16 | $-0.21 | $-0.15 | $-0.19 | $-0.17 | $-0.23 | $-0.22 | $-0.30 | $-0.30 | $-0.31 | $-0.18 | $-0.26 | $-0.29 | $-0.32 | $-0.29 | $-0.33 | $-0.34 | $-0.39 | $-0.28 | $-0.34 | $-0.58 | $-0.41 | $-0.42 | $-0.31 |
| High Forecast | $-0.05 | $-0.10 | $-0.11 | $-0.19 | $-0.10 | $-0.15 | $-0.15 | $-0.21 | $-0.15 | $-0.19 | $-0.17 | $-0.23 | $-0.20 | $-0.26 | $-0.29 | $-0.31 | $-0.17 | $-0.25 | $-0.29 | $-0.32 | $-0.29 | $-0.32 | $-0.33 | $-0.38 | $-0.28 | $-0.34 | $-0.57 | $-0.41 | $-0.41 | $-0.31 |
| Low Forecast | $-0.05 | $-0.10 | $-0.11 | $-0.19 | $-0.11 | $-0.15 | $-0.16 | $-0.21 | $-0.15 | $-0.21 | $-0.17 | $-0.23 | $-0.23 | $-0.33 | $-0.30 | $-0.31 | $-0.18 | $-0.26 | $-0.29 | $-0.32 | $-0.29 | $-0.33 | $-0.34 | $-0.39 | $-0.28 | $-0.34 | $-0.59 | $-0.42 | $-0.42 | $-0.32 |
| Surprise % | - | - | - | - | - | - | - | - | - | - | - | - | - | 0.66% | 0.37% | 0.45% | 0.52% | 1.05% | - | 1.03% | 1.03% | -6.60% | 1.07% | 0.98% | 1.50% | 0.32% | 0.35% | 1.01% | 1.00% | 0.79% |
According to 6 Wall Street analysts, AtriCure's projected average Quarter EPS for Dec 21 is $-0.29, with a low estimate of $-0.29 and a high estimate of $-0.29. This represents a -113.49% decrease compared to ATRC previous annual EPS of $2.15 (Sep 21).
ATRC Forecast FAQ
Is AtriCure a good buy?
Yes, according to 5 Wall Street analysts, AtriCure (ATRC) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 5 'Buy' recommendations, accounting for 100.00% of ATRC's total ratings.
What is ATRC's price target?
AtriCure (ATRC) average price target is $49.57 with a range of $26 to $81, implying a 75.72% from its last price of $28.21. The data is based on 5 Wall Street analysts who provided a twelve-month price target estimate in the last three months.
Will AtriCure stock go up soon?
According to Wall Street analysts' prediction for ATRC stock, the company can go up by 75.72% (from the last price of $28.21 to the average price target of $49.57), up by 187.13% based on the highest stock price target, and down by -7.83% based on the lowest stock price target.
Can AtriCure stock reach $40?
ATRC's average twelve months analyst stock price target of $49.57 supports the claim that AtriCure can reach $40 in the near future.
What are AtriCure's analysts' financial forecasts?
AtriCure's analysts financial forecasts for the fiscal year (Dec 2025) are as follows: average revenue is $520.3M (high $523.78M, low $516.82M), average EBITDA is $-108M (high $-107M, low $-108M), average net income is $-29.091M (high $-28.839M, low $-29.343M), average SG&A $365.79M (high $368.23M, low $363.34M), and average EPS is $-0.62 (high $-0.615, low $-0.626). ATRC's analysts financial forecasts for the fiscal year (Dec 2026) are as follows: average revenue is $580.66M (high $584.54M, low $576.78M), average EBITDA is $-120M (high $-119M, low $-121M), average net income is $-21.475M (high $-21.289M, low $-21.662M), average SG&A $408.22M (high $410.95M, low $405.49M), and average EPS is $-0.458 (high $-0.454, low $-0.462).
Did the ATRC's actual financial results beat the analysts' financial forecasts?
Based on AtriCure's last annual report (Dec 2023), the company's revenue was $399.24M, beating the average analysts forecast of $386.35M by 3.34%. Apple's EBITDA was $-26.683M, missing the average prediction of $-73.544M by -63.72%. The company's net income was $-30.438M, missing the average estimation of $-54.903M by -44.56%. Apple's SG&A was $253.14M, missing the average forecast of $269.21M by -5.97%. Lastly, the company's EPS was $0, missing the average prediction of $-1.136 by -100.00%. In terms of the last quarterly report (Sep 2023), AtriCure's revenue was $98.29M, beating the average analysts' forecast of $96.65M by 1.70%. The company's EBITDA was $-8.089M, missing the average prediction of $-19.969M by -59.49%. AtriCure's net income was $-9.055M, missing the average estimation of $-14.284M by -36.61%. The company's SG&A was $61.6M, missing the average forecast of $67.95M by -9.33%. Lastly, the company's EPS was $-0.2, missing the average prediction of $-0.305 by -34.32%